Skip to main content
-

IBA Launches versatile high-energy new Cyclotron

  IBA leverages 35 years of experience and innovation in the new Cyclone® IKON with enhanced availability of theranostic radiopharmaceuticals and reduced radiopharmacy footprint   Louvain-la-Neuve, Belgium,  10 June 2021 -  IBA (Ion Beam Applications S.A., EURONEXT), the world's leading provider of solutions for the diagnosis and treatment of cancer, today launches its new high energy and high-capacity cyclotron, the Cyclone® IKON, which offers the largest energy spectrum for PET and SPECT isotopes from 13 MeV to 30 MeV. The Cyclone® IKON was showcased during a virtual live event and the replay can be watched here. Currently, there are still a large number of patients for whom cancer treatment fails, despite major scientific advances. Nuclear medicine is emerging as a relevant modality to address this gap by extending overall survival and quality of life for cancer patients. Theranostics and targeted therapies allow the administration of radiation directly to the targeted cells, with minimal toxic side effects to surrounding healthy cells, unlike traditional modalities. The growing number of clinical trials (200+) and ongoing increase of new radiotherapeutic molecule developments support the great potential of radioligand therapy.   “To enable this revolution, we must enhance the availability of novel isotopes and boost their production capacity. In its role, the cyclotron must be a reliable and sustainable production source of isotopes for the radiopharmaceutical industry and this is particularly the case for Germanium-68 (used for Germanium-68/Gallium-68 generators), Iodine-123 and other radioisotopes such as Copper-64, for which the demand has been consistently expanding year after year.” Bruno Scutnaire, Vice-President of IBA's RadioPharma Solutions Division commented. To address these new market needs, IBA has redesigned its previous model, Cyclone® 30 MeV, and created a next generation system, the Cyclone® IKON. It is more compact and versatile than ever and is capable of working over a large energy span (13 to 30MeV) with full current capacity to enable the large-scale and high-purity production of emerging PET, SPECT and “parent” isotopes.  The first two units of the Cyclone® IKON have already been acquired by two leading companies in radiopharmaceuticals production: The Institute of Radioelements (IRE) in Belgium and Curium Pharma in St Louis, USA. Commissioning is scheduled for 2023. Renaud Dehareng, CEO of Curium Pharma said: “IBA has been a trusted partner of Curium for a long time. We selected IBA for its globally recognized expertise and due to the outstanding capabilities and reliability of the Cyclotron.” We selected IBA because of the reliability of its equipment. It has the most compact and efficient high energy cyclotron on the market." said Erich Kollegger, CEO of IRE.    
See more
-

IBA Business Update – First Quarter 2021

Louvain-La-Neuve, Belgium, 20 May 2021 - IBA (Ion Beam Applications S.A., EURONEXT), the world’s leading provider of proton therapy solutions for the treatment of cancer, today announces its business update for the first quarter ending 31 March 2021. Group Overview ▪ Strong balance sheet maintained, with EUR 152 million unaudited gross cash (31 Dec 2020: EUR 151.3 million) and EUR 72.6 million unaudited net cash (31 Dec 2020: EUR 65.2 million) ▪ Business operations have remained solid into the first quarter of 2021, albeit with some continuing impact from COVID-19 related installation delays in Proton Therapy alongside some Other Accelerator delays ▪ Continued focus on sustainable growth and profitability, delivering the very best offering and services to our customers, whilst remaining committed to corporate responsibility ▪ As part of a long-term employee incentive plan, IBA’s share buyback program was launched in January 2021 and is almost complete Olivier Legrain, Chief Executive Officer of IBA commented: “I have been pleased to see IBA’s continued resilience in the first quarter of 2021, with growing momentum in Proton Therapy in the US, continued success in Asia and strong performance in our Dosimetry and Other Accelerators businesses.” “Our roadmap to sustainable growth and profitability is clear: capitalize on our market leading position globally, invest for strategic impact and deliver operational execution. This focus will be reinforced by our continuing commitment to our customers, our employees and to the planet and I am proud of the groundwork we are laying as a company towards a true stakeholder approach to our business.”
See more
-

IBA Reports Full Year 2020 Results

RESILIENT PERFORMANCE ACROSS BUSINESS LINES GOOD ORDER INTAKE AND RECORD BACKLOG POSITIVE REBIT AND BOTTOM LINE STRONG BALANCE SHEET WITH EUR 65 MILLION NET CASH AT YEAR END Louvain-la-Neuve, Belgium, 25 March 2021 - IBA (Ion Beam Applications SA), the world’s leading provider of proton therapy solutions for the treatment of cancer, today announces its consolidated annual results for the 2020 financial year.   Olivier Legrain, Chief Executive Officer of IBA commented: “I am very proud of IBA’s good performance and resilience in what has been a challenging year globally. Our long-term strategy aims to build upon our solid business foundation to create sustainable growth and profitability, delivering the very best offering and services to our customers, whilst being a responsible corporate citizen. Our roadmap to achieve this across all four of our business lines is clear: capitalize on our market leading position globally, invest for strategic impact and deliver operational execution. “A key strategic growth market for us is Asia, particularly China, and we were pleased to sign two significant proton therapy deals in the region in the second half of 2020, as well as a strategic partnership with CGNNT in China. We also delivered strong sales in this region for our Industrial, RadioPharma and Dosimetry businesses. This momentum has continued in 2021, with IBA being selected for the supply of a new Proteus®PLUS solution in China. “Our pipeline continues to be encouraging and overall, order intake across all business units remains buoyant. This, coupled with our growing recurring revenues in Services and Dosimetry, provides us with confidence for the future. I am grateful for the incredible work of the IBA team over the past year, as well as the continued support of our customers. With a healthy balance sheet and the long-term potential for market development across all four of our businesses, we enter 2021 in a confident position.” Financial summary ▪ Total order intake of EUR 112 million for Proton Therapy and Other Accelerators (excluding CGNNT contract) and EUR 54 million for Dosimetry ▪ Total 2020 Group revenues of EUR 312 million, up 10.4%, strongly boosted by the strategic licensing deal with CGN Nuclear Technology Application Co Ltd (CGNNT) ▪ Strong growth in Proton Therapy Services for the third consecutive year, up 7.2% from 2019 ▪ Equipment and Services backlog conversion delayed due to effects of pandemic but remains at all time high of EUR 1.1 billion ▪ Significant increase to full year REBIT, with a profit of EUR 40.4 million (2019: EUR 0.1 million) ▪ Total Group net profit of EUR 31.9 million (2019: EUR 7.6 million) ▪ Very strong balance sheet with EUR 151.3 million gross cash (2019: EUR 46 million) and EUR 65.2 million net cash position (2019: net debt of EUR -21.3 million), with all bank covenants met at year-end ▪ Total direct COVID-19 impact for 2020 estimated to be around EUR 15 million ▪ The Board of Directors will recommend to the annual general assembly the distribution of a total dividend of EUR 0.2 per share, in line with the transition to a new dividend policy Business summary ▪ Proteus®PLUS* licensing deal with Chinese partner CGNNT worth minimum of EUR 100 million announced during the year, with EUR 63.5 million revenues recognized in 2020 ▪ Four-room contract for a Proteus®PLUS Proton Therapy Solution announced in Chengdu, Sichuan Province, China ▪ Contract signed with the National Cancer Center (NCC) Korea for a Proteus®ONE* solution, following a competitive tender process. NCC is already an IBA customer, having previously purchased a three-room Proteus®PLUS solution ▪ Strong order intake for Other Accelerators with 17 systems sold, of which 12 were signed in the second half ▪ Resilient performance of Dosimetry with a strong order intake in the year to date, up 10% from 2019 ▪ Strong cost control measures still in place, partially offsetting COVID-19 related impact, whilst allowing for strategic investments in R&D ▪ Board strengthened with appointment of Ms. Christine Dubus and Dr Richard Hausmann as Non-Executive Directors Post-period highlights ▪ In January, IBA was selected for the supply of a multi-room Proteus®PLUS solution in China, with contract negotiations ongoing ▪ In February, IBA received the third payment related to the CGNNT contract, for EUR 20 million, bringing total cash received to date on this contract to EUR 70 million ▪ In March, IBA received the first down payment on the NCC Korea contract signed in December 2020.
See more
-

IBA and NorthStar Medical Radioisotopes Expand Collaboration to Enable Global Availability of Diagnostic Radioisotope Technetium-99m (Tc-99m)

− Technetium-99m is the daughter isotope of molybdenum-99 (Mo-99) − Collaboration enables integrating technology expertise to provide Tc-99m Generation Systems (TCM Generation Systems) that utilize non-uranium based Mo-99 produced using electron beam accelerators − Diagnostic imaging studies using Tc-99m inform healthcare decisions for approximately 30 million patients annually around the world   Louvain-La-Neuve, Belgium, and BELOIT, Wis., USA March 8, 2021 – IBA (Ion Beam Applications S.A., EURONEXT), the world’s leading provider of proton therapy solutions for the treatment of cancer, and  NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for medical imaging and therapeutic applications, today announced a collaboration to increase global availability of technetium-99m (Tc-99m), the most widely used medical radioisotope. The collaboration enables companies outside of the United States to access the Tc-99m Generation Systems (TCM Generation Systems) that utilize NorthStar’s proprietary non-uranium based Mo-99 produced using IBA’s accelerators and beamlines.   The collaboration builds on an existing contract under which IBA is providing NorthStar with up to eight Rhodotron® TT 300-HE electron beam accelerators. They will be used for the production of non-uranium based Mo-99, which enables NorthStar’s FDA-approved and commercially available RadioGenix® System (technetium Tc 99m generator) to produce Tc-99m in the United States. NorthStar’s Accelerator Production facility expansion is nearing completion in Beloit, Wisconsin, with the first pair of IBA accelerators due to arrive from Belgium in early April 2021.  “Every year approximately 30 million patients benefit from diagnostic imaging studies using Tc-99m,” said Stephen Merrick, President and Chief Executive Officer of NorthStar. “NorthStar is delighted to expand its collaboration with IBA, as we view them to be an ideal partner to grow the use of non-uranium based Mo-99 to support a sustainable and innovative future for nuclear medicine. Based on their commercial expertise and tailored approach, we believe IBA complements NorthStar’s global vision of delivering innovative solutions that can address critical patient healthcare needs related to medical diagnosis. We are proud to lead the field of nuclear medicine as the only commercialized producer of Mo-99 in the United States, having provided more than two years of stable U.S. commercial production to date. We look forward to deepening our collaboration with IBA and are confident that this joint approach has the potential to make non-uranium Mo-99 the leading worldwide source of Tc-99m.” Olivier Legrain, Chief Executive Officer of IBA, commented, “We are pleased to enter into this expanded collaboration for TCM Generation Systems with NorthStar Medical Radioisotopes to enable more companies to access this vital healthcare diagnostic tool. IBA’s Rhodotron® accelerators provide the most advanced accelerator technology in the world, and we look forward to working with NorthStar in applying innovative solutions to enable reliable radioisotope supply on a global basis and exploring additional productive opportunities in the future.” NorthStar’s Accelerator Production facility expansion in Beloit, Wisconsin,will ensure sustainable domestic Mo-99 supply for the United States through dual production and processing hubs for additional capacity and scheduling flexibility. Pending appropriate licensure and approval, the facility will augment current Mo-99 processing in Columbia, Missouri, conducted in partnership with the University of Missouri Research Reactor (MURR®).
See more

Brochures

Synthera® +

EN RU CN

Cyclone® KIUBE

EN CN RU

IntegraLab ONE

EN RU

IntegraLab PLUS

EN CN RU

Videos

IBA Synthera +

IBA Synthera +

Synthera®+ remains the most compact module on the market: up to 3 synthesizers can fit into a standard hot cell. Synthera®+ and Synthera®+ HPLC have both been fully redesigned to meet the most demanding production schedule of different radiotracers without opening the hot cell (less intervention, more safety). Synthera®+ can be equipped with the automatic IFP Loader (disposable production cassette dispenser) which can stack up to 4 cassettes. This allows it to perform consecutive runs of different compounds without opening the hot cell, resulting in nearly zero radiation exposure to the operator. This unique feature multiplies the capability of each module by a factor of four.

yves

IBA is launching a new cyclotron for its 35th anniversary.

Users Meeting 2019 - Krasnoyarsk

Users Meeting 2019 - Krasnoyarsk

IBA organizes biennial users meetings involving all PET customers all around the world. Our experience shows that gathering people together encourages creativity and helps IBA to develop priorities jointly with customers.

KIUBE

IBA integralab presentation - short version

INTEGRALAB®PLUS is a fully integrated solution, combining equipment and services for establishing a radiopharmaceutical GMP production centre tailored to your precise needs. Our approach is truly comprehensive, taking your project from building design through to ongoing production with full regulatory compliance and the selection, integration, installation and qualification of equipment that meets your radioisotope production goals